Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes

The recruitment status of this study is unknown because the information has not been verified recently.

Verified January 2007 by Taichung Veterans General Hospital.
Recruitment status was Recruiting

Sponsor:

Collaborator:

Tri-Service General Hospital

Information provided by:

Taichung Veterans General Hospital

ClinicalTrials.gov Identifier:

NCT00417950

First received: January 1, 2007

Last updated: January 3, 2007

Last verified: January 2007

History of Changes

Tracking Information

First Received Date ^ICMJE

January 1, 2007

Last Updated Date

January 3, 2007

Start Date ^ICMJE

January 2007

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Postprandial hyperglycemia

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00417950 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Postprandial inflammatory responses
Postprandial oxidative stress

Original Secondary Outcome Measures ^ICMJE

Same as current

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes

Official Title ^ICMJE

Not Provided

Brief Summary

To understand if acarbose, an alpha-glucosidase inhibitor usually for treating diabetes, will further lower post meal glucose and inflammatory state when taking together with moderate amount of alcohol during meal tolerance test in subjects with impaired glucose tolerance or mild diabetes.

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Not Provided

Study Design ^ICMJE

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Condition ^ICMJE

Diabetes Mellitus
Impaired Glucose Tolerance

Intervention ^ICMJE

Drug: Acarbose

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Enrollment ^ICMJE

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Subjects with mild diabetes without prior medications or impaired glucose tolerance

Exclusion Criteria:

Pregnancy
Recent major cardiac, renal and hepatic disease
Intolerance to alcohol
Allergy to acarbose treatment

Gender

Both

Ages

25 Years to 75 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: I Te Lee, MD, MS

886-4-23592525 ext 3065

itlee@vghtc.gov.tw

Location Countries ^ICMJE

Taiwan

Administrative Information

NCT Number ^ICMJE

NCT00417950

Other Study ID Numbers ^ICMJE

950801/C06138

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Taichung Veterans General Hospital

Collaborators ^ICMJE

Tri-Service General Hospital

Investigators ^ICMJE

Principal Investigator:

Wayne H Sheu, MD, PhD

Taichung Veterans General Hospital

Information Provided By

Taichung Veterans General Hospital

Verification Date

January 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top